title: [Management of pre-term labor: use of nifedipine in Conakry, Guinea].
abstract: This purpose of this prospective and descriptive study was to evaluate the utility of a calcium-channel inhibitor, i.e. nifedipine, for management of preterm labor in our work setting in terms of safety and cost-effectiveness in comparison with betamimetics classically used for this indication. Study was carried out over a six-month period in the department of Gynecology-Obstetrics Department of Ignace Deen National Hospital in Conakry, Guinea. Pregnant women meeting the following criteria were included: 28 to 33 weeks of amenorrhea, six days of hospitalization either for preterm labor or for another diagnosis that was associated with the occurrence of preterm labor during hospitalization, and absence of contraindications for tocolysis using nifedipine. A total of 42 women were included. Pregnancy was extended for more than 48 hours after the first dose of nifedipine in 86.8% of cases. Administration of nifedipine failed in 5 cases including one case in which it was necessary to change the tocolytic and 4 cases in which delivery occurred less than 48 hours after the first dose of nifedipine. In 68% of cases, 90 mg of nifedipine were sufficient to stop uterine contractions within 48 hours. In 39.5% of cases, no side effects were observed. Adverse effects in the other cases were dizziness (39.5%) and headache (18.4%). The mean term of delivery was 36 weeks +/- 5 days of amenorrhea with a mean extension of 6.2 weeks. Apgar score was low in 30.5% of the newborns and normal in 69.5%. One newborn (2.8%) died. The results of this study indicate that nifedipine is an effective, economical and safe drug for tocolysis and that it can be used as an alternative to betamimetis in countries with limited resources. An information campaign is needed to promote use of nifedipine as a tocolytic in obstetrical facilities of our country.
authors.affiliation: Service de gynécologie-obstétrique, CHU Ignace Deen, Conakry, Guinée. sytelly@yahoo.fr
authors.forename: T
authors.initials: T
authors.lastname: Sy
authors.forename: F B
authors.initials: FB
authors.lastname: Diallo
authors.forename: Y
authors.initials: Y
authors.lastname: Diallo
authors.forename: M K
authors.initials: MK
authors.lastname: Camara
authors.forename: A
authors.initials: A
authors.lastname: Diallo
authors.forename: M
authors.initials: M
authors.lastname: Cissoko
authors.forename: G R
authors.initials: GR
authors.lastname: Lontsi
authors.forename: M S
authors.initials: MS
authors.lastname: Diallo
mesh_terms: D001034:Apgar Score; D036861:Delivery, Obstetric; D004244:Dizziness / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007231:Infant, Newborn; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D011247:Pregnancy; D012449:Safety; D013997:Time Factors; D015149:Tocolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014590:Uterine Contraction / Q000187:drug effects
chemical_list: D015149:Tocolytic Agents; D009543:Nifedipine